An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.

Research output: Contribution to journal › Article › peer-review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{29773b274d144a5baa67ee7a72d4a8e6,

title = "An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.",

author = "CN Sternberg and ID Davis and KC Deen and E Sigal and RE. Hawkins",

year = "2014",

month = sep,

day = "6",

doi = "10.1159/000366227",

language = "English",

volume = "87",

pages = "342--350",

journal = "Oncology",

issn = "0030-2414",

publisher = "S. Karger AG",

number = "6",

}

TY - JOUR

T1 - An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.

AU - Sternberg, CN

AU - Davis, ID

AU - Deen, KC

AU - Sigal, E

AU - Hawkins, RE.

PY - 2014/9/6

Y1 - 2014/9/6

U2 - 10.1159/000366227

DO - 10.1159/000366227

M3 - Article

SN - 0030-2414

VL - 87

SP - 342

EP - 350

JO - Oncology

JF - Oncology

IS - 6

ER -